JP2024521450A5 - - Google Patents

Info

Publication number
JP2024521450A5
JP2024521450A5 JP2023576169A JP2023576169A JP2024521450A5 JP 2024521450 A5 JP2024521450 A5 JP 2024521450A5 JP 2023576169 A JP2023576169 A JP 2023576169A JP 2023576169 A JP2023576169 A JP 2023576169A JP 2024521450 A5 JP2024521450 A5 JP 2024521450A5
Authority
JP
Japan
Prior art keywords
nhc
pharmaceutically acceptable
och
acceptable salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521450A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032691 external-priority patent/WO2022261221A1/en
Publication of JP2024521450A publication Critical patent/JP2024521450A/ja
Publication of JP2024521450A5 publication Critical patent/JP2024521450A5/ja
Pending legal-status Critical Current

Links

JP2023576169A 2021-06-09 2022-06-08 非ペプチド標的治療およびその使用 Pending JP2024521450A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208923P 2021-06-09 2021-06-09
US63/208,923 2021-06-09
PCT/US2022/032691 WO2022261221A1 (en) 2021-06-09 2022-06-08 Non-peptide targeted therapeutics and uses thereof

Publications (2)

Publication Number Publication Date
JP2024521450A JP2024521450A (ja) 2024-05-31
JP2024521450A5 true JP2024521450A5 (enExample) 2025-06-16

Family

ID=84425531

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023572689A Pending JP2024521316A (ja) 2021-06-09 2022-06-08 非ペプチド標的治療薬及びその使用
JP2023576169A Pending JP2024521450A (ja) 2021-06-09 2022-06-08 非ペプチド標的治療およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023572689A Pending JP2024521316A (ja) 2021-06-09 2022-06-08 非ペプチド標的治療薬及びその使用

Country Status (5)

Country Link
US (2) US20240408247A1 (enExample)
EP (2) EP4351653A4 (enExample)
JP (2) JP2024521316A (enExample)
CN (1) CN117377495A (enExample)
WO (2) WO2022261221A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023396827A1 (en) * 2022-12-13 2025-06-19 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
TW202613146A (zh) * 2024-06-11 2026-04-01 美商克林提克斯醫藥股份有限公司 生長抑素亞型-2受體(sst2r)非肽藥物偶聯物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405906B (de) * 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
EP1219305A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
EP1401427A4 (en) * 2001-06-06 2004-12-01 Agouron Pharma NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF, PROCESSES FOR THE PREPARATION THEREOF
CN100356984C (zh) * 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US7771727B2 (en) * 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
CA2556752C (en) * 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
BRPI0510909A2 (pt) * 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
WO2014184682A1 (en) * 2013-04-19 2014-11-20 Oslo Universitetssykehus Hf Radiolabeled gnrh antagonists as pet imaging agents
CA2925651A1 (en) 2013-09-30 2015-04-02 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
CN116726190A (zh) * 2015-06-20 2023-09-12 杭州多禧生物科技有限公司 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
CA3050094C (en) * 2017-01-12 2024-01-02 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
MX2019009419A (es) 2017-02-08 2019-10-02 Ono Pharmaceutical Co Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo.
NZ757081A (en) 2017-03-16 2023-03-31 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
KR102724812B1 (ko) * 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
TWI852944B (zh) 2018-09-18 2024-08-21 美商克林提克斯醫藥股份有限公司 生長抑制素(somatostatin)調節劑及其用途

Similar Documents

Publication Publication Date Title
CN115286697B (zh) 一种双重靶向化合物及其制备方法和应用
AU2019356168B2 (en) Imaging agents
JP6661010B2 (ja) ペプチドチオ尿素誘導体、これを含有する放射線同位体標識化合物、およびこれを活性成分として含有する前立腺癌を処置または診断するための医薬組成物
TWI852782B (zh) 一種成纖維細胞活化蛋白FAP和整合素αvβ3雙重靶向化合物及其製備方法和應用
US9776977B2 (en) PSMA-targeting compounds and uses thereof
JP2019218375A (ja) ニューロテンシン受容体リガンド
JP2020518673A5 (enExample)
CN101784192A (zh) 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
JP2014515750A (ja) 標的型造影剤及びその使用
JP2014501714A5 (enExample)
CN105939732A (zh) 分子成像探针
CN115583989B (zh) 一种靶向sstr2的化合物及其制备方法和应用
CN116751259A (zh) 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法
WO2024193724A1 (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
WO2026037323A1 (zh) 放射性核素标记的靶向pd-l1小蛋白及其制备方法与应用
JP7844752B2 (ja) Ｒｇｄ二量体化合物およびその調製方法と使用
JP2018502150A (ja) 造影剤およびその用途
WO2026037324A1 (zh) 一种靶向pd-l1的核素蛋白探针及其应用
TW202327665A (zh) 基於肽的新型診斷劑和治療劑
WO2025124439A1 (zh) Fap靶向放射性药物
JP2001521515A (ja) キレート化剤
US11504439B2 (en) Radioactive compound for diagnosis of malignant melanoma and use thereof
US11155553B2 (en) Reinforced macrocyclic ligands, complexes thereof, and uses of same
TW201927343A (zh) 癌症診斷中之經放射標記的前胃泌激素
CN121991028A (zh) 靶向c-Met的化合物、基于其的放射性核素标记配合物，以及它们的应用